The global AI in oncology for analytical solutions market size is expected to reach USD 7.4 billion by 2030. The market is expected to expand at a CAGR of 35.5% from 2023 to 2030. The increasing demand to reduce healthcare costs is expected to be a crucial factor driving the adoption of artificial intelligence (AI) in oncology for analytical solutions. The implementation of artificial intelligence algorithms in oncology can significantly improve the accuracy of procedures and reduce the costs associated with treatment by avoiding unnecessary tests. For instance, a June 2021 study published in Frontiers found that incorporating artificial intelligence in the diagnosis of colorectal cancer helped save around USD 400 million, primarily due to the early detection of cancer.
The high prevalence of cancer-related diseases worldwide is expected to drive the expansion during the forecast period. For example, the American Cancer Society, Inc. estimates that by the end of 2022, there will be nearly 1.9 million new diagnoses and 609,360 cancer-related deaths in the U.S. Additionally, lung, breast, rectal, and colon cancers were the most common cancers in February 2022, according to the World Health Organization. Moreover, a third of global cancer deaths are attributed to high body mass index, tobacco use, and lack of physical activity. Therefore, the increasing prevalence of this disease globally is expected to increase the adoption of artificial intelligence for more accurate diagnosis, contributing to the growth of the AI in oncology analytical solutions market.
The market is anticipated to grow due to improvements in healthcare infrastructure and the increasing prevalence of cancer. By utilizing artificial intelligence technology, healthcare providers can diagnose and plan treatment procedures with greater ease. The use of artificial intelligence enables earlier and more accurate detection, reducing treatment costs and enhancing the patient experience through personalized treatment. Additionally, the growth is fueled by initiatives from government and non-government organizations that invest in healthcare R&D. For instance, the Indian government plans to introduce healthcare infrastructure programs worth USD 6.8 billion, according to a recent report from IBEF.
The key players in the AI in the oncology for analytical solutions market are engaging in various strategies including mergers, acquisitions, product launches, and collaboration, which is expected to drive growth during the forecast period. For instance, in November 2022, RadNet, Inc., a provider of cost-effective, high-quality outpatient diagnostic imaging services, announced that its subsidiary Aidence, which specializes in lung artificial intelligence, has entered into an agreement with Google Health, to license later artificial intelligence research model for predicting lung nodule malignancy on CT imaging. Aidence will further develop and validate the model, and bring it to the market to support early and accurate lung cancer diagnosis, as well as reduce the need for unnecessary screening procedures. The market is also growing due to the increasing presence of new entrepreneurial startups that offer innovative solutions for treating and accurately forecasting its development. For instance, a UK-based sta
rtup the Concr is a provider of a software platform that employs a machine learning method that is based on an extensive understanding of scientific projections to forecast how tumors will progress and to more accurately predict how cancer will evolve in response to treatment.
The high prevalence of cancer-related diseases worldwide is expected to drive the expansion during the forecast period. For example, the American Cancer Society, Inc. estimates that by the end of 2022, there will be nearly 1.9 million new diagnoses and 609,360 cancer-related deaths in the U.S. Additionally, lung, breast, rectal, and colon cancers were the most common cancers in February 2022, according to the World Health Organization. Moreover, a third of global cancer deaths are attributed to high body mass index, tobacco use, and lack of physical activity. Therefore, the increasing prevalence of this disease globally is expected to increase the adoption of artificial intelligence for more accurate diagnosis, contributing to the growth of the AI in oncology analytical solutions market.
The market is anticipated to grow due to improvements in healthcare infrastructure and the increasing prevalence of cancer. By utilizing artificial intelligence technology, healthcare providers can diagnose and plan treatment procedures with greater ease. The use of artificial intelligence enables earlier and more accurate detection, reducing treatment costs and enhancing the patient experience through personalized treatment. Additionally, the growth is fueled by initiatives from government and non-government organizations that invest in healthcare R&D. For instance, the Indian government plans to introduce healthcare infrastructure programs worth USD 6.8 billion, according to a recent report from IBEF.
The key players in the AI in the oncology for analytical solutions market are engaging in various strategies including mergers, acquisitions, product launches, and collaboration, which is expected to drive growth during the forecast period. For instance, in November 2022, RadNet, Inc., a provider of cost-effective, high-quality outpatient diagnostic imaging services, announced that its subsidiary Aidence, which specializes in lung artificial intelligence, has entered into an agreement with Google Health, to license later artificial intelligence research model for predicting lung nodule malignancy on CT imaging. Aidence will further develop and validate the model, and bring it to the market to support early and accurate lung cancer diagnosis, as well as reduce the need for unnecessary screening procedures. The market is also growing due to the increasing presence of new entrepreneurial startups that offer innovative solutions for treating and accurately forecasting its development. For instance, a UK-based sta
rtup the Concr is a provider of a software platform that employs a machine learning method that is based on an extensive understanding of scientific projections to forecast how tumors will progress and to more accurately predict how cancer will evolve in response to treatment.
AI In Oncology For Analytical Solutions Market Report Highlights
- Based on cancer type, breast cancer dominated with a share of 30.8% in 2022, owing to a growing demand for use of AI to detect, diagnose, and treat breast cancer.
- The bladder cancer segment is anticipated to witness the fastest growth over the forecast period from 2023 to 2030.
- In 2022, the software solution segment accounted for the highest share of 57.1% in the market, owing to the rising entrepreneurial startups that provide innovative solutions for treatment and accurately predicting cancer.
- The data licensing services segment is expected to witness the fastest growth over the forecast period from 2023 to 2030.
- North America dominated the market in 2022 with a share of over 58%. The availability of digital infrastructure, and favorable government and reimbursement policies are some of the key factors responsible for the growth of the market in the region. Rising reimbursements offered by the governments in the region is anticipated to boost the adoption of oncology services in the region.
- Asia Pacific is projected to witness a fastest growth over the forecast period from 2023 to 2030. This growth can be attributed to several factors such as the increasing elderly population in countries including India and Japan and the growing adoption of digital technologies in hospitals and diagnostic facilities.
Table of Contents
Chapter 1. Methodology and Scope1.1. Market Segmentation and Scope
1.2. Market Definition
1.3. Research Methodology
1.3.1. Information Procurement
1.3.1.1. Purchased database
1.3.1.2. internal database
1.3.2. Primary Research
1.4. Research Scope and Assumptions
1.5. List to Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
2.4. AI in Oncology for Analytical Solutions Market
Chapter 3. AI in Oncology for Analytical Solutions Market Variables, Trends, & Scope
3.1. Penetration and Growth Prospect Mapping
3.2. Market Dynamics
3.3. AI in Oncology for Analytical Solutions Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of the suppliers
3.3.1.2. Bargaining power of the buyers
3.3.1.3. Threats of substitution
3.3.1.4. Threats from new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic and Social landscape
3.3.2.3. Technological landscape
3.3.3. Impact of COVID-19 on the market
Chapter 4. AI in Oncology for Analytical Solutions Market: Component Type Estimates & Trend Analysis
4.1. Definitions & Scope
4.2. AI in Oncology for Analytical Solutions Market: Component Type Movement Analysis, 2021 & 2030 (USD Million)
4.3. Data Licensing Services
4.3.1. Data licensing service market estimates and forecasts, 2018 - 2030 (USD Million)
4.3.1.1 Payers
4.3.1.1.1 Payers market estimates and forecasts, 2018 - 2030 (USD Million)
4.3.1.2 Providers
4.3.1.2.1 Providers market estimates and forecasts, 2018 - 2030 (USD Million)
4.3.1.3 Pharmaceutical
4.3.1.3.1 Pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
4.4. Software solutions
4.4.1. Software solutions market estimates and forecasts, 2018 - 2030 (USD Million)
4.4.1.1 Payers
4.4.1.1.1 Payers market estimates and forecasts, 2018 - 2030 (USD Million)
4.4.1.2 Providers
4.4.1.2.1 Providers market estimates and forecasts, 2018 - 2030 (USD Million)
4.4.1.3 Pharmaceutical
4.4.1.3.1 Pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
4.5. Analytics and other services
4.5.1. Analytics and other services market estimates and forecasts, 2018 - 2030 (USD Million)
4.5.1.1 Payers
4.5.1.1.1 Payers market estimates and forecasts, 2018 - 2030 (USD Million)
4.5.1.2 Providers
4.5.1.2.1 Providers market estimates and forecasts, 2018 - 2030 (USD Million)
4.5.1.3 Pharmaceutical
4.5.1.3.1 Pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 5. AI in Oncology for Analytical Solutions Market: Cancer Type Estimates & Trend Analysis
5.1. Definitions and Scope
5.2. AI in Oncology for Analytical Solutions Market: Cancer Type Movement Analysis, 2021 & 2030 (USD Million)
5.3. Breast Cancer
5.3.1. Breast Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
5.4. Lung Cancer
5.4.1. Lung Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
5.5. Prostate Cancer
5.5.1. Prostate Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
5.6. Colorectal Cancer
5.6.1. Colorectal Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
5.7. Brain Tumor
5.7.1. Brain Tumor market estimates and forecasts, 2018 - 2030 (USD Million)
5.8. Kidney cancer
5.8.1. Kidney cancer market estimates and forecasts, 2018 - 2030 (USD Million)
5.9. Non-Hodgkin lymphoma
5.9.1. Non-Hodgkin lymphoma market estimates and forecasts, 2018 - 2030 (USD Million)
5.10. Bladder cancer
5.10.1. Bladder cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 6. AI in Oncology for Analytical Solutions Market: Regional Estimates & Trend Analysis
6.1. Regional Market Snapshot
6.2. AI in Oncology for Analytical Solutions Market: Regional Movement Analysis
6.3. North America
6.3.1. North America market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.3.2. North America market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.3.3. U.S.
6.3.3.1. U.S. market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.3.3.2. U.S. market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.3.4. Canada
6.3.4.1. Canada market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.3.4.2. Canada market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.4. Europe
6.4.1. Europe market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.4.2. Europe market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.4.3. Germany
6.4.3.1. Germany market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.4.3.2. Germany market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.4.4. U.K.
6.4.4.1. U.K. market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.4.4.2. U.K. market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.4.5. France
6.4.5.1. France market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.4.5.2. France market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.4.6. Italy
6.4.6.1. Italy market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.4.6.2. Italy market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.4.7. Spain
6.4.7.1. Spain market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.4.7.2. Spain market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.4.8. Russia
6.4.8.1. Russia market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.4.8.2. Russia market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.5. Asia Pacific
6.5.1. Asia Pacific market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.5.2. Asia Pacific market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.5.3. Japan
6.5.3.1. Japan market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.5.3.2. Japan market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.5.4. China
6.5.4.1. China market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.5.4.2. China market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.5.5. India
6.5.5.1. India market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.5.5.2. India market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.5.6. Australia
6.5.6.1. Australia market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.5.6.2. Australia market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.5.7. South Korea
6.5.7.1. South Korea market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.5.7.2. South Korea market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.6. Latin America
6.6.1. Latin America market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.6.2. Latin America market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.6.3. Brazil
6.6.3.1. Brazil market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.6.3.2. Brazil market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.6.4. Mexico
6.6.4.1. Mexico market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.6.4.2. Mexico market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.6.5. Argentina
6.6.5.1. Argentina market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.6.5.2. Argentina market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.6. MEA
6.6.1. MEA market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.6.2. MEA market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.6.3. South Africa
6.6.3.1. South Africa market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.6.3.2. South Africa market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.6.4. Saudi Arabia
6.6.4.1. Saudi Arabia market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.6.4.2. Saudi Arabia market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
6.6.5. UAE
6.6.5.1. UAE market estimates and forecasts, by component 2018 - 2030 (USD Million)
6.6.5.2. UAE market estimates and forecasts, by cancer type 2018 - 2030 (USD Million)
Chapter 7. AI in Oncology for Analytical Solutions Market - Competitive Analysis
7.1. Company Market Share Analysis, 2022 (%), by component type
7.1.1. Data Licensing Services
7.1.2. Software Solutions
7.1.3. Analytics and Other Services
7.2. Competition Categorization
7.3. Company Market Position Analysis
7.4. Company Profiles of each of the players
7.4.1. Company Overview
7.4.2. Product/Solution Benchmarking
7.4.3. Financial Performance
7.5.4. Strategic Initiatives
7.5. Some of the key players
7.5.1. Flatiron Health
7.5.2. Tempus AI
7.5.3. Medidata Solutions
7.5.4. GNS Healthcare
7.5.5. GNS Healthcare
7.5.6. Oracle
7.5.7. Cancer Research Horizons
List of Tables
Table 1 Factors used in segment share estimation
Table 2 List of secondary data sources
Table 3 Primary interview details, by source
Table 4 Primary interview details, by region
Table 5 North America market estimates and forecasts, by country, 2018 - 2030 (USD Million)
Table 6 North America market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 7 North America market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 8 U.S. market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 9 U.S. market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 10 Canada market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 11 Canada market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 12 Europe market estimates and forecasts, by country, 2018 - 2030 (USD Million)
Table 13 Europe market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 14 Europe market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 15 Germany market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 16 Germany market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 17 U.K. market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 18 U.K. market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 19 France market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 20 France market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 21 Italy market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 22 Italy market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 23 Spain market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 24 Spain market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 25 Russia market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 26 Russia market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 27 Asia Pacific market estimates and forecasts, by country, 2018 - 2030 (USD Million)
Table 28 Asia Pacific market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 29 Asia Pacific market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 30 Japan market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 31 Japan market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 32 China market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 33 China market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 34 India market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 35 India market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 36 Australia market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 37 Australia market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 38 Singapore market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 39 Singapore market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 40 South Korea market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 41 South Korea market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 42 Latin America market estimates and forecasts, by country, 2018 - 2030 (USD Million)
Table 43 Latin America market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 44 Latin America market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 45 Brazil market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 46 Brazil market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 47 Mexico market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 48 Mexico market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 49 Argentina market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 50 Argentina market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 51 MEA market estimates and forecasts, by country, 2018 - 2030 (USD Million)
Table 52 MEA market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 53 MEA market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 54 South Africa market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 55 South Africa market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 56 Saudi Arabia market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 57 Saudi Arabia market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
Table 58 UAE market estimates and forecasts, by component type, 2018 - 2030 (USD Million)
Table 59 UAE market estimates and forecasts, by cancer type, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data Triangulation Techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market Snapshot
Fig. 9 AI in Oncology for Analytical Solutions Market variables, trends & scope
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Market restraint relevance analysis (Current & future impact)
Fig. 12 Company/Competition Categorization
Fig. 13 Company market position analysis
Fig. 14 Component market share analysis, 2022 & 2030
Fig. 15 Segment Dashboard
Fig. 16 Data licensing services market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 17 Data licensing services payers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 Data licensing services providers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 Data licensing services pharmaceutical market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Software solutions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Software solutions payers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Software solutions providers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Software solutions pharmaceutical market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Analytics and other services market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Analytics and other services payers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Analytics and other services providers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Analytics and other services pharmaceutical market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Cancer type market share analysis, 2022 & 2030
Fig. 29 Segment Dashboard
Fig. 30 Breast cancer market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Lung cancer market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Prostate cancer market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Colorectal cancer market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Brain tumor market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Kidney market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Non-hodgkin lymphoma market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Bladder cancer market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Regional market place: Key takeaways
Fig. 39 AI in Oncology for Analytical Solutions Market: Regional outlook, 2021 & 2030 (USD Million)
Fig. 40 North America market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 U.S. market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Canada market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Europe market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Germany market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 U.K. market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 France market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Italy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Spain market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Russia market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Asia Pacific market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Japan market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 China market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 India market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Australia market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 South Korea market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Latin America market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Brazil market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Mexico market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Argentina market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 MEA market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 South Africa market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Saudi Arabia market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 UAE market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Companies Mentioned
- Flatiron Health
- Tempus AI
- Medidata Solutions
- GNS Healthcare
- GNS Healthcare
- Oracle
- Cancer Research Horizons
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | March 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 612.3 Million |
| Forecasted Market Value ( USD | $ 7400 Million |
| Compound Annual Growth Rate | 35.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 7 |
